The global burden of hepatocellular carcinoma (HCC) is significant. As the fifth most common malignancy and the third leading cause of cancer-related deaths worldwide, 1 HCC occurs most frequently in the setting of chronic liver injury and cirrhosis. Geographic variation in incidence is primarily related to patterns of infection with hepatitis B and hepatitis C. Although the incidence is particularly high in Asian countries related to endemic hepatitis B, HCC is on the rise in developed countries due to the consequences of hepatitis C. In the United States, the HCC age-adjusted incidence rate has doubled in recent decades, 2 including an apparent increased incidence and mortality among American Indians and Alaska natives. 
Introduction
The global burden of hepatocellular carcinoma (HCC) is significant. As the fifth most common malignancy and the third leading cause of cancer-related deaths worldwide, 1 HCC occurs most frequently in the setting of chronic liver injury and cirrhosis. Geographic variation in incidence is primarily related to patterns of infection with hepatitis B and hepatitis C. Although the incidence is particularly high in Asian countries related to endemic hepatitis B, HCC is on the rise in developed countries due to the consequences of hepatitis C. In the United States, the HCC age-adjusted incidence rate has doubled in recent decades, 2 including an apparent increased incidence and mortality among American Indians and Alaska natives. Other risk factors for HCC include alcoholic liver disease, steatohepatitis, hemochromatosis, and aflatoxin exposure.
Despite improved treatment of viral hepatitis and increased screening of high-risk patients in developed countries, only around 40% of patients diagnosed with HCC are eligible for potentially curative treatments (resection, transplantation, or local ablation) and 20% for chemoembolization. The remaining 40% of patients present with advanced disease. 3 Thus, systemic therapy is indicated for a considerable proportion of patients with HCC.
The development of effective systemic therapies for HCC has been challenging (Table 1) . First, tumor biology dictates poor chemosensitivity, which is frequently related to the expression of drug resistance genes. Overexpression of drug efflux pumps such as P-glycoprotein and multidrug resistance protein increases the cellular outflow of cytotoxic agents. Second, the hepatic dysfunction that contributes to the development of most HCCs (60% to 80%) hinders the delivery of drug therapy. Cirrhosis not only impairs drug metabolism, but also affects the manufacture of plasma-binding proteins that influence the serum proportion of active drug. Additionally, the accumulation of fluid that occurs with cirrhosis can alter drug distribution volumes. 4 Furthermore, HCC outcomes are difficult to measure. Because this tumor often arises in a diseased liver, cirrhosis-related deaths may confound the evaluation of drug efficacy. Response Evaluation Criteria in Solid Tumors (RECIST) 5 measures correlate poorly with HCC tumor cell death, and radiographic tumor necrosis may be seen without change, or rarely enlargement, in tumor dimensions. Additionally, response rates may inadequately capture clinical benefit. In the era of targeted therapy, survival benefit has been documented in the absence of objective tumor regression, and clinical trial endpoints that may be more appropriate include survival, time to recurrences, and time to disease progression. 3 Finally, the inclusion of diverse populations in clinical trials poses questions for therapeutic applicability. For example, Western patients are generally older with a preponderance of hepatitis C and alcohol related cirrhosis, whereas Asian patients are generally younger with hepatitis B and well-preserved hepatic function. Most clinical trials are restricted to patients with ChildPugh A or B liver function, and there remains little to offer patients with poorer hepatic reserve.
Various systems have been proposed for HCC staging, including the American Joint Committee on Cancer (AJCC) TNM (tumor-node-metastasis), BCLC (Barcelona Clinic Liver Cancer), CLIP (Cancer of the Liver Italian Program), Okuda, CUPI (Chinese University Prognostic Index), JIS (Japanese Integrated System), and GRETCH (Groupe d'Etude et de Traitement du Carcinoma Hepatocellulaire). With the exception of TNM, which is based solely on tumor characteristics, most staging algorithms use a combination of tumor status, liver function, and performance status (Table 2 ). In one study comparing seven staging systems, the BCLC system provided the best independent prediction for survival among a cohort of 239 consecutive patients with HCC. 6 Liver function is generally estimated by the Child-Pugh classification of liver disease.
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Systemic Chemotherapy Doxorubicin Doxorubicin ushered in the era of chemotherapeutics in HCC. Since the 1970s, it has been considered one of the most active cytotoxic agents. An initial trial conducted in Uganda with 14 patients heralded an impressive 79% response rate. 8 Subsequent studies, however, have indicated more limited activity, with response rates for single-agent doxorubicin around 10% to 20%. 9, 10 Whether doxorubicin prolongs survival in patients with HCC remains unclear; however, this has been suggested in several studies. A single trial that randomized 60 patients to doxorubicin vs no therapy showed a significant prolongation in median survival (10.6 vs 7.5 weeks, P = .036) in patients receiving doxorubicin. 11 However, a meta-analysis comparing doxorubicin to no therapy or to other therapies showed no significant survival benefit. 12 However, a drawback to this meta-analysis was the variety of regimens studied in the comparator arm. A more recent study that randomized patients to doxorubicin vs nolatrexed showed longer survival in the doxorubicin arm (32.3 vs 22.3 weeks, P = .007).
However, more study withdrawals due to toxicity were seen in patients treated with nolatrexed and may have negatively biased survival in this arm. 13 Several phase II trials involving other anthracyclines such as epirubicin and liposomal doxorubicin [14] [15] [16] [17] have demonstrated no significant advantage over doxorubicin in terms of improved outcomes or measures of toxicity.
Fluoropyrimidines
Studies using bolus regimens of 5-fluorouracil combined with leucovorin have demonstrated relatively high rates of gastrointestinal toxicity, with response rates ranging from 0% to 28%. 18, 19 Although the toxicity profile associated with oral capecitabine appears to be more manageable, 20 response rates remain relatively low. A study reporting relatively high dihydropyrimidine dehydrogenase (DPD) activity in HCC may explain the chemoresistance seen in fluorouracil-based regimens.
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Other Cytotoxic Agents Although gemcitabine appears highly active in vitro against HCC cell lines, 22 trials utilizing single-agent gemcitabine have shown fairly limited clinical activity. A response rate of 17% was reported in a small Taiwanese trial composed of 28 patients. 23 However, subsequent trials have failed to confirm significant activity, with response rates of only 0% to 2%. [24] [25] [26] Combinations of gemcitabine and platinum derivatives appear more active, and toxicities are manageable in patients with preserved liver function. With combinations of gemcitabine and oxaliplatin, response rates of 15% to 20% and disease stabilization rates of 48% to 58% have been reported in small phase II trials. 27, 28 Irinotecan has minimal clinical activity with substantial toxicity related to its hepatic metabolism and is not recommended for use outside of a clinical trial. 29, 30 Hormonal Therapy Despite the finding that some HCCs express estrogen receptors, most trials evaluating the role of tamoxifen in advanced HCC have found little benefit in terms of response or survival. [31] [32] [33] A recent Cochrane analysis found no evidence for survival benefit in patients treated with tamoxifen vs placebo. 34 Subgroup analysis suggested a possible detrimental effect on survival in patients treated with higher doses of tamoxifen.
Although somatostatin receptors have been identified in HCC specimens, placebo-controlled trials of long-acting somatostatin have failed to show activity in advanced HCC. 35 
Targeted Therapies
In light of the disappointing results seen with traditional systemic chemotherapy, more attention recently has been focused on elucidating molecular targets for the treatment of HCC. 36 By interfering with pathways involved in malignant cell growth and proliferation ( Figure) , targeted agents are designed to hinder tumor progression with minimal toxicity to normal cells. These agents typically prolong survival as a result of disease stabilization rather than objective tumor regression (Table 3) . [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] HCC is a highly vascular tumor, reflecting the activation of pathways involved in angiogenesis. Increased levels of vascular endothelial growth factor (VEGF) have been implicated in the pathogenesis of HCC and have been shown to correlate with tumor recurrence and survival. 49, 50 In addition, aberrations in the mitogen-activated protein kinase (MAPK) pathway have been identified as key signals for the growth and survival of HCC. 51 This signaling pathway consists of the cellular kinases MAPK, ras, raf, MEK, and ERK. In one study, overexpression of MAPK was detected by immunohistochemistry in 91% of 46 HCCs examined. 52 In addition, detection of phosphorylated MEK1/2 was more frequent with advancing tumor stage.
Sorafenib
Sorafenib is a multikinase inhibitor with activity against c-Raf, b-Raf, vascular endothelial growth factor receptor (VEGFR), c-KIT, and platelet-derived growth factor receptor beta (PDGFR-β), which are important in tumor cell proliferation and angiogenesis. Preclinical studies showed potent antitumor activity in HCC cell lines and xenograft models. 53 Subsequently, a phase II clinical trial was conducted in 137 patients with advanced HCC. 37 Most patients (72%) had Child-Pugh A liver function, while the remainder had Child-Pugh B. Sorafenib was given continuously at 400 mg twice daily. Although objective responses were few -3 patients had a partial response and 8 had a minor response -approximately one-third has stable disease and median survival was an encouraging 9.2 months. In a subset of patients with biomarker correlation, significantly longer time to progression was seen in patients with tumors showing higher pretreatment pERK staining intensity. This led to the randomized phase III Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial conducted primarily in European centers. 38 The trial randomized 602 patients with advanced HCC and Child-Pugh A liver function to receive sorafenib or placebo. The study was stopped at an interim analysis due to a survival advantage seen in the sorafenib arm (10.7 months vs 7.9 months, P = .00058). Time to progression was also significantly longer in patients treated with sorafenib (5.5 months vs 2.8 months, P < .0001), although the response rate was negligible at 2%. Treatment was relatively well tolerated; the only grade 3/4 toxicities more common in the sorafenib group were diarrhea (8% vs 2%) and handfoot syndrome (8% vs < 1%). Within this trial, subgroup analysis indicated a benefit for sorafenib in patients with hepatitis C, with a median survival advantage of 14 months compared with 10.7 months for the whole sorafenib treatment group. Similarly, a retrospective analysis of the phase II trial of sorafenib in patients with HCC indicated that those with hepatitis C (13 patients) had longer time to progression compared with those with hepatitis B (33 patients) (12.4 vs 7.3 months, P = .29). 54 A plausible explanation may be the amplified raf kinase activity observed in HCV-1 core protein. 55 A phase III study of similar design was conducted in Asian and Pacific centers. 39 In contrast to the SHARP study, patients were younger, had poorer performance status, and were more frequently infected with hepatitis B. Additionally, tumors had more vascular involvement and extrahepatic spread. Nevertheless, a survival benefit of similar magnitude was seen despite lower values for overall survival (6.5 vs 4.2 months) and time to progression (2.8 vs 1.4 months). Grade 3/4 toxicities more prevalent than those in the placebo arm included diarrhea, hand-foot syndrome, and fatigue.
In both phase III trials of sorafenib, entry criteria were limited to patients with Child-Pugh A liver function. Information regarding the use of sorafenib in patients with Child-Pugh B disease comes from subset analysis of 38 patients in the phase II trial. 56 According to this report, serious adverse events were seen in 52% of patients with Child-Pugh A vs 68% of patients with ChildPugh B. Elevated bilirubin, worsening encephalopathy, and worsening ascites were more common in patients with Child-Pugh B, although it is difficult to ascertain whether this worsening of hepatic function was related to sorafenib administration or progression of underlying disease. Pharmacokinetic analysis was comparable in these two groups, and rates of discontinuation and dose reduction were similar. It should be noted that sorafenib can cause elevations in bilirubin via inhibition of uridine disphosphate-glucuronosyltransferase (UGT) 1A1.
The utility of sorafenib in patients with moreadvanced disease, including Child-Pugh B (26%) and C (3%), was evaluated in 51 patients in a phase II trial conducted at a single institution in Hong Kong. 57 Demographic data revealed that 90% of patients had hepatitis B and 6% had hepatitis C, while 47% were stage IV. Responses occurred in 8%, and 18% had stable disease for at least 3 months. Median overall survival was 5 months. The absence of extrahepatic metastasis, particularly the absence of lung metastasis, predicted clinical benefit. No difference in benefit was observed between Child-Pugh A and B/C in overall survival (5.5 months vs 5 months, P = .24). Similarly, there were no significant differences in grade 3/4 hematologic toxicities, nonhematologic toxicities or, more importantly, in liver function derangement between Child-Pugh A and B/C.
The combination of sorafenib and doxorubicin was compared to doxorubicin alone in a randomized phase II trial. 40 In a preliminary report including 96 patients with Child-Pugh A liver function, overall survival was an encouraging 13.8 months for the combination arm vs 6.5 months for doxorubicin alone. However, left ventricular dysfunction (any grade) was seen in 19% of patients receiving the sorafenib-doxorubicin combination. This combination requires further careful clinical investigation before entering the clinical compendium.
Sunitinib
Sunitinib is an oral inhibitor of multiple tyrosine kinases, including VEGFR, PDGFR, KIT, RET, and FLT3. A European/Asian phase II study explored the safety and efficacy of sunitinib dosed at 50 mg daily for 4 of 6 weeks in 37 patients with unresectable HCC. 46 Although only one partial response was confirmed, stable disease was noted in approximately 40%, and imaging evidence of tumor necrosis was seen in 46% of patients. However, significant rates of grade 3/4 toxicities were seen, including thrombocytopenia (43%), neutropenia (24%), CNS symptoms (24%), asthenia (22%), and hemorrhage (14%). Four patients had fatal treatment-related events.
Two subsequent phase II trials showed improved tolerability of sunitinib using a dose of 37.5 mg daily for 4 of 6 weeks. 58, 59 Similar rates of response were noted, with few partial responses and stable disease in 35% to 40%. Grade 3/4 toxicities included elevated serum glutamic-oxaloacetic transaminase (alanine aminotransferase), in 18% lymphopenia in 15%, neutropenia, fatigue, and thrombocytopenia in 12%, and hyperbilirubinemia, hypertension, hand-foot syndrome, and rash in 6%. 58 These preliminary data indicate activity similar to that of sorafenib, albeit with a different toxicity profile and no definitive confirmation of survival benefit. An ongoing phase III trial will compare the efficacy of sorafenib vs sunitinib.
Bevacizumab
Bevacizumab is a recombinant humanized monoclonal antibody directed at VEGF. In a phase II trial of 46 patients, bevacizumab was given as a single agent at 5 mg/kg or 10 mg/kg. 41 Objective responses were seen in 13% of patients, and median progression-free and overall survival were 6.9 months and 12.4 months, respectively. As an intriguing correlate, significant reductions in tumor arterial enhancement on MRI and reductions in circulating VEGF were seen with bevacizumab. The most common grade 3/4 toxicities were hypertension (15%), thrombosis (6%), and hemorrhage (11%). A fatal variceal bleed was noted in the second enrolled patient, which resulted in a protocol amendment requiring endoscopy and treatment of patients with a history of esophageal varices or evidence of varices on pretreatment imaging studies.
The combination of erlotinib and bevacizumab showed encouraging activity in a cohort of 40 patients with advanced HCC and Child-Pugh A or B liver function. 42 Partial responses were seen in 25% of patients, and 62% were progression-free at 16 weeks. The median overall survival was 15.7 months. Grade 3/4 adverse events included side effects expected from the individual agents such as fatigue (20%), hypertension (15%), diarrhea (10%), and elevated transaminases (10%). The incidence of grade 3/4 gastrointestinal hemorrhage was significant in this trial as well, involving 12.5% of patients. After the trial protocol was amended to include screening for varices and required adequate treatment of esophageal varices prior to protocol enrollment, no further variceal hemorrhages were seen.
In a trial combining gemcitabine, oxaliplatin, and bevacizumab, 60 efficacy was similar to the previously published gemcitabine/oxaliplatin combination. Toxicities were predictable and consistent with those of the individual agents, with the exception of a fairly high incidence (27%) of grade 3 hypertension. Grade 3 gastrointestinal bleeding was seen in 3 patients, and 1 patient experienced bowel perforation.
EGFR Inhibitors
Overexpression of the EGFR has been identified in a significant portion of HCCs. Erlotinib is an oral tyrosine kinase inhibitor targeting the intracellular domain of EGFR. A phase II study utilizing erlotinib at a dose of 150 mg daily in 38 previously treated patients with advanced HCC demonstrated partial responses in 3 patients. 43 The progression-free survival rate was 32% at 6 months, and overall survival was a respectable 13 months. Grade 3/4 adverse effects included rash (13%), diarrhea (8%), and fatigue (8%). A second phase II trial of erlotinib in previously untreated patients revealed no objective responses. 44 However, nearly half of the 40 patients achieved stable disease over 16 weeks of treatment, and the medial survival was 10.8 months. It should be noted that EGFR expression did not correlate with outcome in either study.
Cetuximab is a chimeric monoclonal antibody targeting the EGFR. In a phase II study that evaluated 30 patients treated with cetuximab alone, 5 patients had stable disease with no responses seen. The median overall survival was 9.6 months and progression-free survival was 1.4 months. Treatment was well tolerated, but no significant antitumor activity was seen. Cetuximab trough concentrations were not found to be notably altered in patients with moderate hepatic dysfunction. 45 In a study involving 45 patients with advanced HCC using the combination of gemcitabine and oxaliplatin (GEMOX) with the addition of cetuximab, there were 9 partial responses that lasted 2 to 14 months. 61 Stable disease was observed in 40%, with an overall disease control rate of 60%. Progression-free survival and overall survival were 4.7 and 9.5 months, respectively. No statistical difference was seen according to the degree of cetuximab-related skin toxicity (grade 2-3 vs grade 0-1), and toxicity was manageable with no toxic deaths. It is unclear at this time whether the addition of cetuximab offers additional benefit over the GEMOX combination alone.
mTOR Inhibitors
The kinase cascade that includes phosphoinositide-3 kinase (PI3K), protein kinase B (Akt), and mammalian target of rapamycin (mTOR) is associated with progression through the cell cycle and is a key regulator of cell growth, survival, and proliferation. 62 Sirolimus, temsirolimus, and everolimus (RAD 001) are mTOR inhibitors already in clinical use. Sirolimus is used as an immunosuppressant following transplantation of solid organs, and temsirolimus and everolimus are approved for the treatment of renal cell carcinoma.
The mTOR pathway is activated in approximately 50% of HCCs. 63 In a mouse model of HCC, sirolimus reduced tumor growth and vascularity. 64 A pilot study of sirolimus in patients with advanced HCC included 14 patients with cirrhosis. 48 Responses were noted in 40% (partial response in 5 patients and complete response in 1 patient). Drug-related toxicities included mucositis, fatigue, and skin toxicity. Combinations of mTOR inhibitors with doxorubicin and cisplatin in experimental models have shown additive antitumoral effects, 65, 66 although these results await confirmation in clinical trials. Global studies of sirolimus and everolimus in patients with HCC are ongoing.
Immunotherapy
With less than optimal conventional systemic treatments for HCC, there has been interest in novel immunotherapy strategies that may be employed to render a cancer more immunogenic, generate antigen-specific or nonspecific immune activation, and/or manipu-late the tumor microenvironment. Despite extensive genetic changes found in HCC, these cancers are not clinically immunogenic in both mice and humans. 67 Expression of major histocompatibility complex (MHC) class II, which can activate CD4+ helper T cells, is lacking. HCC also has suboptimal expression of adhesion and costimulatory molecules that signal effector cells. This defect may be mitigated through various immunologic approaches. 68 Antigen-presenting cells (APCs), especially dendritic cells (DCs), can express adhesion and costimulatory molecules to give strong second signals, and therapies exploiting this point have been created to stimulate immunity. 69, 70 Cytokines can increase MHC expression for improved antigen presentation and possibly skew the immune response toward activation of cytotoxic T cells. 71, 72 It seems logical that immunotherapy strategies for HCC have to elicit an antitumor response through both prevention and response.
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Cytokines
Interferons have immunomodulatory and antiproliferative properties as well as antiangiogenic properties, and they have been used to treat a variety of malignancies including HCC. Interferon alfa (IFN-α) was evaluated in two randomized trials for the treatment of advanced HCC with conflicting results. 73, 74 A Chinese trial conducted in the 1980s comparing IFN-α with no therapy showed a marginal survival advantage (14.5 vs 7.5 weeks, P = .047), 73 but a more recent randomized European trial demonstrated poor drug tolerance and no survival benefit. 74 Considerable interest has been given to a regimen combining cisplatin, interferon, doxorubicin, and 5-fluorouracil (PIAF). Although this regimen is toxic, complete responses have been reported. 75 A randomized phase III trial 76 comparing PIAF with doxorubicin showed a higher response rate (20.9% vs 10.5%) and improved overall survival (8.7 months vs 6.8 months) for PIAF, but it produced more neutropenia, thrombocytopenia, and hypokalemia. A subsequent analysis of 149 patients treated with PIAF identified "good-risk patients" as those with no cirrhosis and a bilirubin level of ≤ 0.6 mg/dL. In these patients, the response rate to PIAF was 50%. Thus, PIAF may be considered for a selected subgroup of HCC patients, particularly those with preserved liver function in whom downstaging may be desired to facilitate future tumor resection.
Lygidakis et al 77 treated 20 stage III-IV HCC patients with transarterial chemotherapy combined with interferon gamma (IFN-γ) and interleukin 2 (IL-2). Fourteen subjects had a response with decreased tumor size and decreased levels of serum α-fetoprotein (AFP). 81 in 1995 performed trials combining doxorubicin with lymphocyte-activated killer (LAK) cells generated from splenocytes following resection. In this LAK-based therapy, the patients' peripheral blood lymphocytes (obtained via leukapheresis) were treated with IL-2 cytokine stimulation in vitro that was subsequently reinfused. Whereas the 1991 study 80 showed a decreased rate of recurrence, the 1995 study 81 showed no benefit. Wang et al 82 treated 10 patients with tumor-infiltrating lymphocytes (TILs) activated by IL-2 and LAK cell supernatant; this TIL therapy involves harvesting tumor-infiltrating lymphocytes from the tumor itself and then isolating the cells by growing single-cell suspensions from the tumor. After several weeks of culture in vitro in the presence of IL-2, the activated TIL cells were transfused back into the patient. Treated subjects were reported to have improved recurrence rates compared to historical controls. Takayama et al 83 studied 150 patients who received either IL-2 and anti-CD3-activated peripheral blood lymphocytes (PBLs) or observation following curative resection. This trial found statistically significant improvements in risk of recurrence, time to recurrence, and recurrence-free survival. However, overall survival fell short of statistical significance (P = .09). Finally, Shi et al 84 tested cytokine-activated PBLs, cultured in IFN-γ, anti-CD3, and IL-2, in 13 HCC patients to determine biologic endpoints. The percentage of DCs in the peripheral blood improved.
Antigen-Presenting Cells
Several groups have explored DC ex vivo generated from peripheral blood, pulsed with HCC tumor or HCC tumor lysate with variable response. Ladhams et al 85 treated 2 patients diagnosed with metastatic HCC with immature DCs grown in granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4 with the intention of blocking macrophage development from monocyte precursors; one had slower HCC growth compared to pretreatment status. Iwashita et al 86 used DCs loaded with tumor lysate, stimulated with tumor necrosis factor alfa (TNF-α), and then mixed with keyhole limpet hemocyanin (KLH) before injection. Of the 10 patients with unresectable HCC who were treated, 7 developed positive delayed-type hypersensitivity (DTH) responses to KLH. In addition, 1 patient had a mixed tumor response. However, Stift et al 87 performed a study with tumor lysate-loaded DCs matured with TNF-α and mixed with IL-2 for patients with a variety of solid tumors. The 2 patients with HCC did not respond. Lee et al 88 treated 31 HCC patients with DCs pulsed with autologous tumor lysate. Four patients had a partial response and 17 patients had stable disease. In addition, the 17 monthly boosted patients had a 1-year survival rate of 63%. Overall, treated patients were reported to have a significantly improved 1-year survival rate (40%) compared with historical controls (20%, P = .038). DCs have also been tested in combination with external beam radiotherapy. Chi et al 89 studied 14 patients who received 8 Gy of radiotherapy followed by 1 to 2 doses of immature DCs intratumorally. Toxicity was clinically insignificant. Three patients had a reduced serum AFP level, and 8 of 10 patients had AFP-specific immunologic improvements.
Thus, immunotherapy can result in the regression of bulky, invasive cancer in a few patients, but currently available therapies are less successful than desired. 90 By employing novel tools in combination with immunotherapy, such as advanced imaging 91 and imageguided radiation therapy, 92 further immunologic manipulations may be translated from bedside to bench and back again. 
Conclusions
Systemic therapy is appropriate for patients who are not candidates for surgical resection or liver transplantation and have failed or are unsuitable for locoregional therapies. A paucity of data has been published to date on the safety of targeted therapies combined with chemo-or radioembolization, and this course of therapy is not currently recommended outside of clinical trials. For patients eligible for systemic therapy, enrollment on a clinical protocol is preferred. When a clinical trial is not available or when a patient is ineligible, sorafenib is recommended starting at 400 mg orally twice daily. Phase II data support the administration of sorafenib in patients with Child-Pugh B liver function. However, the phase III trials, which demonstrated a survival benefit for sorafenib, enrolled only patients with Child-Pugh A liver function.
Alternate systemic chemotherapy may be considered for patients who retain a good performance status and preserved liver function despite disease progression on sorafenib. Although the optimal regimen has not been established, reasonable options include doxorubicin, capecitabine, or gemcitabine/platinum combinations. A number of promising targeted therapies are awaiting confirmation of efficacy in larger, randomized trials. Immunotherapy remains an investigational approach only.
The demonstration of a survival benefit with sorafenib has not only opened new avenues of investigation into the molecular carcinogenesis of HCC and the search for biomarkers predictive of response, but also clearly established the role of targeted therapies in this relatively chemoresistant tumor. Rational combinations of sorafenib and other targeted agents are currently being tested in the clinical arena. In addition, combinations of targeted agents with traditional chemotherapy are being explored. There is ongoing evaluation of the safety and efficacy of targeted agents in the setting of chemoembolization and as adjuncts to HCC resection or liver transplantation. Due to hepatic impairment in the majority of patients, careful safety evaluation as well as pretreatment risk group stratification in these analyses are needed.
As newer agents and combinations are studied, it will be important to evaluate them in the context of a patient population with well-defined hepatic function using appropriate radiologic response criteria and meaningful clinical endpoints. Furthermore, the association of outcomes with molecular correlates may help to define the population most likely to benefit from a particular therapy. Similarly, the development of hepatitis prevention and treatment trials is a fertile area for clinical research.
The treatment of patients with HCC remains challenging and requires a multidisciplinary approach. Recent progress in this malignancy provides renewed impetus to search basic avenues for targeted agents and to implement meaningful clinical trials that may benefit patients worldwide.
